Silexion Therapeutics Announces 1-for-10 Reverse Share Split

What Happened Silexion Therapeutics Corp. (SLXN) announced a 1‑for‑10 reverse share split of all issued, outstanding and authorized but unissued ordinary shares effective May 28, 2026. The split was approved by shareholders at an extraordinary general meeting (initially held April 28, 2026 and reconvened May 5, 2026). The company’s shares began trading on a post‑split basis on the Nasdaq Capital Market at the open on May 29, 2026. Silexion has retroactively adjusted its audited financial statements for the year ended December 31, 2025 and its interim financial statements for the quarter ended March 31, 2026 to reflect the reduced share count and increased per‑share amounts; those updated statements are attached to the 8‑K.

Key Details

• Reverse split ratio: 1-for-10 (effective date May 28, 2026).
• Trading post-split on Nasdaq began: May 29, 2026 (ticker SLXN).
• Financial statements adjusted retroactively: audited statements as of/for year ended Dec 31, 2025 and interim statements as of/for quarter ended Mar 31, 2026.
• Updated audited and unaudited statements were filed as exhibits to the 8‑K.

Why It Matters A reverse share split reduces the number of outstanding shares and increases the per‑share price without changing the company’s market value (absent market reaction). For investors, this can affect metrics reported on a per‑share basis (EPS, NAV per share) and may influence liquidity, share price perception, and compliance with listing requirements. The company has restated recent financial statements so historical per‑share figures and option/warrant information now reflect the new share count.